NCT01027624已完成不适用
Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 3,000
- 试验地点
- 1
- 主要终点
- Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
研究概览
简要总结
This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be 18 years of age or older of either gender or race.
- •Subject must provide informed consent and comply with the survey procedures.
- •Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
排除标准
- •Subjects who are unwilling or unable to provide informed consent.
结局指标
主要结局
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
次要结局
- Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to the Fourth Joint European Task Force Guidelines/South African Guidelines in primary/secondary prevention patients, patients with metabolic syndrome
- Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III
- Proportion of patients on lipid-lowering pharmacological treatment reaching the non HDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Guidelines
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and LebanonHigh Blood CholesterolNCT01614561AstraZeneca1,000
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)DyslipidaemiaNCT02230241AstraZeneca2,700
已完成
不适用
Centralized Pan-Asian Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemiaNCT00687492AstraZeneca8,000
已完成
不适用
InPractice Survey on the Treatment of HypercholesterolemiaHypercholesterolemiaNCT00523796AstraZeneca2,500